A recent study revealed a new development in the transplantation of blood -forming stem cells that will enable blood cancer patients to obtain safe and effective transplants that may heal their illness from non -identical donors.
The process of implanting the blood -forming stem cells, which is sometimes referred to as bone marrow transplantation, includes giving healthy blood stem cells from a donor to patients with bone marrow defects.
This procedure has many benefits, and it can be used to treat malignant and non -malignant conditions, as it improves bone marrow functions, and it can produce healthy cells that replace unsafe cells in some cases such as HIV.
The study was conducted by researchers from several centers in the United States, including the Center for International Blood and Cruisted Research, Minynabolis, Minnesota, Hematology and Oncology Department, Virginia Health University, Virginia, and published the results of the study in Journal of Clinical ONCOLOGY on July 16, and wrote about the Yorik Alert website.
Stay alive
Patients who were unable to find a donor who has an ideal match for cell transplants usually due to the possibility of bait against the host, and this happens when the immune system recognizes the cultivated cells as strange and attacking them, this may be dangerous, and in some cases, it may be fatal.
The new study found that the treatment approach using cyclofosfamide can prevent most cases of bait against the host, and cyclosfamide, a drug used to treat a number of cancers and discharge the immune system.
The researchers continued 145 patients who received the treatment of cycloposfamide, and found that 8 out of 10, or about 80%, remained alive after a year. This is similar to the results observed in studies conducted on patients who received completely identical implants.
“This study is important because all patients, regardless of their backgrounds, now they have a donor to the cultivation of stem cells or bone marrow, which is a great progress in our field, our patients and our society.” Stated by Dr. Karen Balin, head of the Department of Blood and Oncology and Medical Director for Stem Cell Promotion at the University of Virginia and the researcher participating in the study.
The experiment participants were suffering from leukemia, lymphoma, or porridge defect syndrome, and they were unable to find completely compatible donors, underwent a partially compatible peripheral stem cell transplant, and they were given cyclophosphamide to prevent bait against the host.